If approved, TALVEY® plus daratumumab will be the only GPRC5D-targeting bispecific antibody combination therapy for relapsed or refractory multiple myeloma as early as second lineCHMP recommendation ...

A phase 2 trial found that ultra-low-dose radiation therapy delivered in one or two sessions relieved painful bone lesions in ...

A phase 1 clinical trial found that an investigational CAR-T therapy can lead to deep and durable responses in people with relapsed or refractory multiple myeloma.

A retrospective cohort study using the MIMIC-IV database found that elevated blood urea nitrogen within 24 hours of ICU ...

With the FDA approval of Zenbexus this summer, Bristol Myers Squibb checked off two notable ‘firsts,’ scoring the inaugural ...

Louis Prevost, brother of Pope Leo XIV, is facing the challenges of multiple myeloma diagnosed back in 2017. Recent health ...

Multiple myeloma is a type of blood cancer caused by a buildup of abnormal plasma cells in the bone marrow. As the abnormal plasma cells accumulate, they crowd out healthy cells and cause symptoms ...

Ralph V. Boccia, MD, FACP, compared MRD data with Tec-Dara and Tal-Dara and explained how sustained MRD negativity is reshaping myeloma care.

Black Americans are more likely to develop multiple myeloma and are often diagnosed at a younger age. The reasons are not fully understood but may involve biological and genetic factors. MGUS, a ...

Louis Prevost was reportedly diagnosed with the blood cancer in 2017.

Multiple myeloma, a blood cancer, can lead to various eye problems due to complications such as hyperviscosity syndrome (thickened blood) or extramedullary disease (tumor growth outside the bone ...

Johnson & Johnson announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommends the approval of an indication extension of TALVEY® ...